Drug intelligence / Profile preview

LNR 125.36

Development stage: Preclinical
Lead developer: Lanier Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

LNR 125.36 is described as a fully humanized anti-IL-25 monoclonal antibody developed for the treatment of Type 2 Inflammatory diseases, including moderate to severe asthma, chronic sinusitis with nasal polyps, eosinophilic esophagitis and gastritis, chronic urticaria, and atopic dermatitis. Its mechanism involves inhibition of the cytokine IL-25, thereby reducing the activity of downstream allergic and antiviral cytokines associated with Type 2 inflammation. The drug is intended to significantly reduce Type 2 cytokines and inflammatory cells, targeting conditions driven by allergic and non-allergic inflammatory responses[1].

Brand names: LNR 125.36LNR125.36LNR-125.36
Other names: LNR 125.36LNR125.36LNR-125.36

Targets

IL25 (IL-25)

Beyond the preview

Go deeper on LNR 125.36.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNR 125.36.

Explore the full profile